| Celsion stock moving to the Nasdaq
Celsion Corp. will list its shares on the Nasdaq Stock Exchange beginning Feb. 8. The Columbia biotechnology company will make the switch to the Nasdaq from the American Stock Exchange. Celsion's (AMEX: CLN) ticker symbol will remain the same on the Nasdaq, which is well-known as home to technology stocks. On Jan. 18, Celsion received approval from the U.S. Food and Drug Administration to begin international testing of a treatment for liver cancer. The work could begin at 40 sites in North America, Italy, China, Hong Kong, and Korea and will involve more than 600 patients. The trials will study the impacts of ThermoDox, a cancer drug developed by Celsion, when combined with a radiofrequency treatments on liver cancer and tumors.
Hyperthermia Combined with Radiation and Androgen Therapy Provides ...
BSD Medical Corp. (AMEX:BSM) today announced that the International Journal of Hyperthermia has published the preliminary results of a phase II clinical study involving 144 patients with locally advanced prostate cancer. In this study BSD Medical's BSD-2000 hyperthermia system was used to deliver local hyperthermia combined with conformal radiation therapy and androgen suppression therapy in the treatment of prostate cancer. Hyperthermia combined with radiation and androgen therapy demonstrated results in survival similar to treatments using higher radiation doses, with no significant side effects associated with either hyperthermia or radiation therapy. The report is entitled "Conformal radiotherapy plus local hyperthermia in patients affected by locally advanced high risk prostate cancer: Preliminary results of a prospective phase II study" (see Int.
M. D. Anderson Cancer Center to Lead Study of Surgery vs. CyberKnife(R ...
SUNNYVALE, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Accuray Incorporated (NASDAQ: ARAY) , a global leader in the field of radiosurgery, announced today that the company is partnering with The University of Texas M. D. Anderson Cancer Center in Houston, Texas to launch a prospective clinical study to compare treatment outcomes in early-stage operable lung cancer. Patients in the study will be randomly assigned to traditional surgery or CyberKnife(R) Robotic Radiosurgery for their treatment. In the past several years evidence has grown showing excellent outcomes in the treatment of lung tumors with high-dose radiation delivered in three or four treatments. Study results on operable patients treated by these short courses have demonstrated survival rates and local control rates similar to those of traditional surgery.
|
